Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Aramchol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 3,987Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Galmed Pharmaceuticals Extends Aramchol Patent Protection to 2039
    Galmed Pharmaceuticals Extends Aramchol Patent Protection to 2039

    20 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-secures-new-patent-grant-extending-aramchols-patent-protection-to-2039-strengthening-leadership-in-nashmash-combination-therapy-302407043.html

    PR NEWSWIRE
    20 Mar 2025
    Share Share
    Galmed reports results from ARMOR study showing improvements
    Galmed reports results from ARMOR study showing improvements

    04 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-reports-results-from-the-open-label-part-of-the-armor-study-showing-improvements-in-histology-imaging-and-biomarkers-with-aramchol-301713284.html

    PR NEWSWIRE
    04 Jan 2023
    Share Share
    Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in Lung Fibrosis
    Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in Lung Fibrosis

    07 Jul 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-reports-significant-anti-fibrotic-effects-of-aramchol-in-a-lung-fibrosis-model-301582307.html

    PRNEWSWIRE
    07 Jul 2022
    Share Share
    Galmed Continues to Drive Innovation with 3 New US Patents Granted for Aramchol
    Galmed Continues to Drive Innovation with 3 New US Patents Granted for Aramchol

    11 Jan 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-continues-to-drive-innovation-with-three-new-us-patents-granted-for-aramchol-and-its-meglumine-salt-301458242.html

    PRNEWSWIRE
    11 Jan 2022
    Share Share
    Galmed Provides +ve Data from ARMOR Study; Reports Q3 2021 Financial Results
    Galmed Provides +ve Data from ARMOR Study; Reports Q3 2021 Financial Results

    08 Nov 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-provides-additional-positive-data-from-the-open-label-part-of-armor-study-and-reports-third-quarter-2021-financial-results-301418394.html

    PRNEWSWIRE
    08 Nov 2021
    Share Share
    Results of Galmed's Phase 2b ARREST Trial Published in Nature Medicine
    Results of Galmed's Phase 2b ARREST Trial Published in Nature Medicine

    11 Oct 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/results-of-galmeds-phase-2b-arrest-trial-of-aramchol-published-in-nature-medicine-301396857.html

    PRNEWSWIRE
    11 Oct 2021
    Share Share